Illumina, Inc. (NASDAQ:ILMN) is under substantial scrutiny from investors. Although the stock offers a potential upside of over 40%, it experienced several sell-offs. Major firms like
Primecap Management Co. CA and
BI Asset Management Fondsmaeglerselskab A S have reduced their stakes, while others like
Norges Bank and
Kingsview Wealth Management LLC have increased their interests. There's been internal movement with
Anna Richo joining the Board of Directors, and the appointments of
Ankur Dhingra as CFO and
Jakob Wedel as Chief Strategy and Corporate Development Officer.
Illumina's Q1 earnings beat estimates despite a quarterly loss expansion. The company also witnessed growth in its
iHope Genetic Health Program and an investment in seven genomics startups. Despite these positive aspects, investors express concern over low performance metrics and continued sluggish demand impacting the company's annual revenue forecast. Illumina's planned divestiture of
GRAIL has been permitted by the European Commission, aiming to improve its financial position. Analyst recommendations fluctuate, with some forecasting a slow rebound while others downgrade the stock to 'hold'.
Illumina ILMN News Analytics from Sat, 09 Sep 2023 07:00:00 GMT to Sun, 26 May 2024 20:36:50 GMT -
Rating -2
- Innovation 5
- Information 6
- Rumor -3
